Open AccessImmunodynamics of explanted human tumors for immuno‐oncology
Author(s) -
Dubuisson Agathe,
Fahrner JeanEudes,
Goubet AnneGaëlle,
Terrisse Safae,
Voisin Nicolas,
Bayard Charles,
Lofek Sebastien,
Drubay Damien,
Bredel Delphine,
Mouraud Séverine,
Susini Sandrine,
Cogdill Alexandria,
Rebuffet Lucas,
Ballot Elise,
Jacquelot Nicolas,
Thomas de Montpreville Vincent,
Casiraghi Odile,
Radulescu Camélia,
Ferlicot Sophie,
Figueroa David J,
Yadavilli Sapna,
Waight Jeremy D,
Ballas Marc,
Hoos Axel,
Condamine Thomas,
Parier Bastien,
Gaudillat Christophe,
Routy Bertrand,
Ghiringhelli François,
Derosa Lisa,
Breuskin Ingrid,
Rouanne Mathieu,
André Fabrice,
Lebacle Cédric,
Baumert Hervé,
Wislez Marie,
Fadel Elie,
Cremer Isabelle,
Albiges Laurence,
Geoerger Birgit,
Scoazec JeanYves,
Loriot Yohann,
Kroemer Guido,
Marabelle Aurélien,
Bonvalet Mélodie,
Zitvogel Laurence
Publication year - 2020
Publication title -
embo molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.923
H-Index - 107
eISSN - 1757-4684
pISSN - 1757-4676
DOI - 10.15252/emmm.202012850
Subject(s) - humanities , medicine , library science , political science , art , computer science
Decision making in immuno‐oncology is pivotal to adapt therapy to the tumor microenvironment (TME) of the patient among the numerous options of monoclonal antibodies or small molecules. Predicting the best combinatorial regimen remains an unmet medical need. Here, we report a multiplex functional and dynamic immuno‐assay based on the capacity of the TME to respond to ex vivo stimulation with twelve immunomodulators including immune checkpoint inhibitors (ICI) in 43 human primary tumors. This " in sitro" ( in situ / in vitro ) assay has the potential to predict unresponsiveness to anti‐PD‐1 mAbs, and to detect the most appropriate and personalized combinatorial regimen. Prospective clinical trials are awaited to validate this in sitro assay.